The role of monoamine oxidase inhibitors in current psychiatric practice

J Psychiatr Pract. 2004 Jul;10(4):239-48. doi: 10.1097/00131746-200407000-00005.

Abstract

The use of monoamine oxidase inhibitors (MAOIs) by psychiatrists has declined over the past several decades with the expansion of psychiatrists' pharmacologic armamentarium. This trend has also been driven by concern about food and drug interactions and side effects, as well as waning physician experience with these medications. Many psychiatrists, in fact, never prescribe MAOIs. Recent research has liberalized the MAOI diet and identified symptom presentations more likely to respond to these medications. Thus, clinicians must continue to familiarize themselves with the properties of and indications for prescribing MAOIs.

MeSH terms

  • Depressive Disorder / drug therapy*
  • Drug Interactions
  • Humans
  • Monoamine Oxidase Inhibitors / adverse effects*
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Treatment Outcome

Substances

  • Monoamine Oxidase Inhibitors